SCHEMBL2486005

SCHEMBL2486005

OCC/N=C/c1c(Cl)cccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
CHRM1 P11229 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
MAOA P21397 1/20 0.47
DRD1 P21728 1/20 0.47
TBXA2R P21731 1/20 0.47
SLC6A2 P23975 1/20 0.47
ADRA1D P25100 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
SLC6A4 P31645 1/20 0.47
ADRA1A P35348 1/20 0.47
OPRM1 P35372 1/20 0.47
DRD3 P35462 1/20 0.47
HTR2B P41595 1/20 0.47
MTOR P42345 1/20 0.47
SLC6A3 Q01959 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2486006 1.00 SLC22A1 (0.47) SLC22A1HTR1AADRA2ACHRM1ADRA2B
SCHEMBL5382965 0.78 CA2 (0.48) POLBHTTKMT2AMEN1ALDH1A1
SCHEMBL5382962 0.78 CA2 (0.48) POLBHTTKMT2AMEN1ALDH1A1
SCHEMBL2483578 0.76 TAAR1 (0.51) SLC22A1HTR1AADRA2ACHRM1ADRA2B
SCHEMBL2483579 0.76 TAAR1 (0.51) SLC22A1HTR1AADRA2ACHRM1ADRA2B
SCHEMBL16415896 0.75 MAP1LC3B (0.43) MAOASMN1; SMN2POLBHTTKMT2A
SCHEMBL16415897 0.75 MAP1LC3B (0.43) MAOASMN1; SMN2POLBHTTKMT2A
SCHEMBL14543883 0.75 SLC22A1 (0.46) SLC22A1HTR1AADRA2ACHRM1ADRA2B
SCHEMBL5379894 0.72 CA12 (0.54) SMN1; SMN2ALDH1A1CYP1A2LMNATSHR
SCHEMBL5379889 0.72 CA12 (0.54) SMN1; SMN2ALDH1A1CYP1A2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP claimed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP claimed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US claimed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO claimed
EP-3212183-B1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIV ROCHESTER (US) 2019-10-02 EP disclosed
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
EP-3212183-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS University of Rochester (US) 2017-09-06 EP disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed
WO-2016070021-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2016-05-06 WO disclosed
US-8778631-B2 Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system SUTRO BIOPHARMA, INC. (US) 2014-07-15 US disclosed
EP-2376647-B1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA INC (US) 2014-03-05 EP disclosed
EP-2379578-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD Sutro Biopharma, Inc. (US) 2011-10-26 EP disclosed
US-20100184135-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
US-20100184134-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
WO-2010081110-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
WO-2010081111-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP disclosed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP disclosed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US disclosed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 SLC22A1 4066/4885HTR1A 4654/4885ADRA2A 4746/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 SLC22A1 4066/4885HTR1A 4654/4885ADRA2A 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.